Royal Bank of Canada’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-29,597
| Closed | -$90K | – | 7390 |
|
|
2024
Q4 | $90K | Buy |
29,597
+490
| +2% | +$2.13K | ﹤0.01% | 5396 |
|
|
2024
Q3 | $151K | Buy |
29,107
+665
| +2% | +$3.31K | ﹤0.01% | 5043 |
|
|
2024
Q2 | $73K | Sell |
28,442
-66,311
| -70% | -$226K | ﹤0.01% | 5460 |
|
|
2024
Q1 | $467K | Buy |
94,753
+5,425
| +6% | +$32.1K | ﹤0.01% | 4022 |
|
|
2023
Q4 | $786K | Buy |
89,328
+17,065
| +24% | +$140K | ﹤0.01% | 3855 |
|
|
2023
Q3 | $830K | Buy |
72,263
+29,553
| +69% | +$568K | ﹤0.01% | 3585 |
|
|
2023
Q2 | $1.08M | Sell |
42,710
-1,103
| -3% | -$34.4K | ﹤0.01% | 3309 |
|
|
2023
Q1 | $1.41M | Sell |
43,813
-19,879
| -31% | -$620K | ﹤0.01% | 3079 |
|
|
2022
Q4 | $1.18M | Buy |
63,692
+11,320
| +22% | +$259K | ﹤0.01% | 3367 |
|
|
2022
Q3 | $1.41M | Sell |
52,372
-21,065
| -29% | -$427K | ﹤0.01% | 3136 |
|
|
2022
Q2 | $1.01M | Buy |
73,437
+16,973
| +30% | +$261K | ﹤0.01% | 3500 |
|
|
2022
Q1 | $1.1M | Sell |
56,464
-401
| -0.7% | -$6.08K | ﹤0.01% | 3565 |
|
|
2021
Q4 | $928K | Buy |
56,865
+15,281
| +37% | +$255K | ﹤0.01% | 3897 |
|
|
2021
Q3 | $1.16M | Buy |
41,584
+16,971
| +69% | +$484K | ﹤0.01% | 3536 |
|
|
2021
Q2 | $730K | Sell |
24,613
-4,912
| -17% | -$142K | ﹤0.01% | 3937 |
|
|
2021
Q1 | $824K | Sell |
29,525
-9,619
| -25% | -$266K | ﹤0.01% | 3757 |
|
|
2020
Q4 | $1.11M | Buy |
39,144
+13,842
| +55% | +$359K | ﹤0.01% | 3398 |
|
|
2020
Q3 | $636K | Buy |
25,302
+1,080
| +4% | +$28.3K | ﹤0.01% | 3657 |
|
|
2020
Q2 | $592K | Buy |
24,222
+42
| +0.2% | +$829 | ﹤0.01% | 3635 |
|
|
2020
Q1 | $358K | Sell |
24,180
-207
| -0.8% | -$4.28K | ﹤0.01% | 3906 |
|
|
2019
Q4 | $395K | Sell |
24,387
-6,658
| -21% | -$103K | ﹤0.01% | 4138 |
|
|
2019
Q3 | $404K | Sell |
31,045
-753
| -2% | -$9.21K | ﹤0.01% | 3979 |
|
|
2019
Q2 | $412K | Buy |
31,798
+5,068
| +19% | +$63.9K | ﹤0.01% | 3979 |
|
|
2019
Q1 | $422K | Buy |
26,730
+2,501
| +10% | +$43.4K | ﹤0.01% | 3850 |
|
|
2018
Q4 | $488K | Sell |
24,229
-1,530
| -6% | -$33.7K | ﹤0.01% | 3716 |
|
|
2018
Q3 | $640K | Buy |
25,759
+130
| +0.5% | +$3.54K | ﹤0.01% | 3722 |
|
|
2018
Q2 | $704K | Sell |
25,629
-867
| -3% | -$26.1K | ﹤0.01% | 3511 |
|
|
2018
Q1 | $816K | Buy |
26,496
+874
| +3% | +$28.1K | ﹤0.01% | 3329 |
|
|
2017
Q4 | $916K | Sell |
25,622
-1,699
| -6% | -$48.8K | ﹤0.01% | 3297 |
|
|
2017
Q3 | $753K | Buy |
27,321
+3,553
| +15% | +$86.1K | ﹤0.01% | 3468 |
|
|
2017
Q2 | $627K | Buy |
23,768
+3,637
| +18% | +$81.1K | ﹤0.01% | 3491 |
|
|
2017
Q1 | $419K | Sell |
20,131
-609
| -3% | -$12.5K | ﹤0.01% | 3780 |
|
|
2016
Q4 | $429K | Buy |
20,740
+1,205
| +6% | +$20.2K | ﹤0.01% | 3884 |
|
|
2016
Q3 | $317K | Buy |
19,535
+307
| +2% | +$4.46K | ﹤0.01% | 4092 |
|
|
2016
Q2 | $261K | Sell |
19,228
-992
| -5% | -$17.5K | ﹤0.01% | 4218 |
|
|
2016
Q1 | $353K | Buy |
20,220
+13,933
| +222% | +$284K | ﹤0.01% | 3929 |
|
|
2015
Q4 | $214K | Buy |
6,287
+4,897
| +352% | +$170K | ﹤0.01% | 4467 |
|
|
2015
Q3 | $41K | Sell |
1,390
-375
| -21% | -$11.4K | ﹤0.01% | 5242 |
|
|
2015
Q2 | $57K | Buy |
1,765
+1,115
| +172% | +$28.7K | ﹤0.01% | 5157 |
|
|
2015
Q1 | $13K | Sell |
650
-251
| -28% | -$4.34K | ﹤0.01% | 5498 |
|
|
2014
Q4 | $15K | Buy |
901
+251
| +39% | +$4.38K | ﹤0.01% | 5492 |
|
|
2014
Q3 | $13K | Sell |
650
-25,475
| -98% | -$664K | ﹤0.01% | 5407 |
|
|
2014
Q2 | $888K | Buy |
26,125
+14,925
| +133% | +$468K | ﹤0.01% | 2927 |
|
|
2014
Q1 | $353K | Buy |
+11,200
| New | +$350K | ﹤0.01% | 3625 |
|
Other funds holding RVNC
Royal Bank of Canada's RVNC Position: Q1 2025 in Review
Royal Bank of Canada sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 29,597 shares — an estimated $90K sold.
Royal Bank of Canada first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $1.41M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Royal Bank of Canada reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Royal Bank of Canada sold 29,597 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $90K.
- Royal Bank of Canada first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Royal Bank of Canada's Revance Therapeutics, Inc. position peaked at $1.41M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.